Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

BACKGROUND: The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for newer therapeutic targets and modalities is critical. The cell surface glycoprotein B7H3 is expressed on a range of solid tumors with a restricted expression on normal t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramer, Kim, Pandit-Taskar, Neeta, Kushner, Brian H., Zanzonico, Pat, Humm, John L., Tomlinson, Ursula, Donzelli, Maria, Wolden, Suzanne L., Haque, Sophia, Dunkel, Ira, Souweidane, Mark M., Greenfield, Jeffrey P., Tickoo, Satish, Lewis, Jason S., Lyashchenko, Serge K., Carrasquillo, Jorge A., Chu, Bae, Horan, Christopher, Larson, Steven M., Cheung, Nai-Kong V., Modak, Shakeel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655863/
https://www.ncbi.nlm.nih.gov/pubmed/36371226
http://dx.doi.org/10.1186/s13045-022-01383-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655863/
https://www.ncbi.nlm.nih.gov/pubmed/36371226
http://dx.doi.org/10.1186/s13045-022-01383-4

Ejemplares similares